1‐Year distant brain controlNo. of participants: 602(4 RCTs) · patients with newly diagnosed multiple brain metastases
Radiosurgery alone leads to higher 1‐Year distant brain controlNo. of participants: 602(4 RCTs) compared with WBRT and radiosurgery (high certainty).
1 finding from 1 review
HR 2.34 [1.73, 3.18]
Studies not reported
High
Adverse effectsNo. of participants: 1754(9 RCTs) · patients with newly diagnosed multiple brain metastases
1 finding from 1 review
no estimate extracted
Studies not reported
High
NeurocognitionNo. of participants: 403(3 RCTs) · patients with newly diagnosed multiple brain metastases
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Neurological functionNo. of participants: 544(3 RCTs) · patients with newly diagnosed multiple brain metastases
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Quality of lifeNo. of participants: 271(2 RCTs) · patients with newly diagnosed multiple brain metastases
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Overall survival: WBRT 4000 cGy/20 fractions BID vs control WBRT (2000 cGy/4‐5 daily fractions)No. of participants: 203(2 RCTs) · patients with newly diagnosed multiple brain metastases
Altered WBRT fractionation schedules showed no clear difference in overall survival: WBRT 4000 cGy/20 fractions BID vs control WBRT… compared with WBRT control (moderate certainty).
1 finding from 1 review
HR 1.18 [0.89, 1.56]
Studies not reported
Moderate
Adverse effectsNo. of participants: 1754(9 RCTs) · patients with newly diagnosed multiple brain metastases
1 finding from 1 review
no estimate extracted
Studies not reported
High
Symptom controlNo. of participants: 1814(3 RCTs) · patients with newly diagnosed multiple brain metastases
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Overall brain controlNo. of participants: 203(2 RCTs) · patients with newly diagnosed multiple brain metastases
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Neurological function improvement: lower‐dose WBRT vs control dose WBRT (3000 cGy/10 fractions)No. of participants: 1612(5 RCTs) · patients with newly diagnosed multiple brain metastases
Altered WBRT fractionation schedules probably leads to higher neurological function improvement: lower‐dose WBRT vs control dose… compared with WBRT control: neurological function improvement (moderate certainty).
1 finding from 1 review
OR 1.74 [1.06, 2.84]
Studies not reported
Moderate
Neurological function improvement: higher‐dose WBRT vs control dose WBRT (3000 cGy/10 fractions)No. of participants: 1480(4 RCTs) · patients with newly diagnosed multiple brain metastases
Altered WBRT fractionation schedules showed no clear difference in neurological function improvement: higher‐dose WBRT vs control dose… compared with WBRT control: neurological function improvement (moderate certainty).
1 finding from 1 review
OR 1.14 [0.92, 1.42]
Studies not reported
Moderate
Overall survivalNo. of participants: 2631(8 RCTs) · patients with newly diagnosed multiple brain metastases
WBRT with radiosensitisers (radiosen) showed no clear difference in overall survivalNo. of participants: 2631(8 RCTs) compared with WBRT alone (moderate certainty).
1 finding from 1 review
HR 1.05 [0.99, 1.12]
Studies not reported
Moderate
Overall survival (survival until death from all causes) · adult women diagnosed with early stage (I to IIa) endometrial cancer undergoing surgery as primary treatment.
Laparoscopy showed no clear difference in overall survival (survival until death from all causes) compared with laparotomy (moderate certainty).
1 finding from 1 review
Recurrence‐free survival · adult women diagnosed with early stage (I to IIa) endometrial cancer undergoing surgery as primary treatment.
Laparoscopy showed no clear difference in recurrence free survival compared with laparotomy (moderate certainty).
1 finding from 1 review
Serious adverse events (range of outcomes) · adult women diagnosed with early stage (I to IIa) endometrial cancer undergoing surgery as primary treatment.
Laparoscopy showed no clear difference in serious adverse events (range of outcomes) compared with laparotomy (low certainty).
1 finding from 1 review
Rate of symptom relief · women previously treated for endometrial cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Rate of tumour recurrence · women previously treated for endometrial cancer
It is very uncertain whether oestrogen replacement therapy changes rate of tumour recurrence compared with placebo (very low certainty).
1 finding from 1 review
Rate of appearance of a new malignancy · women previously treated for endometrial cancer
It is very uncertain whether oestrogen replacement therapy changes rate of appearance of a new malignancy compared with placebo (very low certainty).
1 finding from 1 review
Rate of survival: overall survival · women previously treated for endometrial cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Progression‐free survival (PSF) · women previously treated for endometrial cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found